Revolo Biotherapeutics is developing revolutionary therapies powered to reset the immune system to achieve superior long-term remission for patients with autoimmune & allergic diseases, while preventing the unwanted effects of chronic immune suppression.
Location: United States, Louisiana, New Orleans
Employees: 11-50
Total raised: $126.36M
Founded date: 2011
Investors 4
| Date | Name | Website |
| 10.09.2022 | NCL Techno... | ncltv.co.u... |
| - | 24Haymarke... | 24haymarke... |
| - | NCL Invest... | nclim.co.u... |
| - | Greenwood ... | gwcinvesto... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 06.10.2020 | Series B | $71.5M | 24Haymarke... |
| 21.09.2020 | Series B | $54M | - |
| 21.06.2020 | - | $864.21K | - |
Mentions in press and media 10
| Date | Title | Description |
| 07.10.2021 | AI-Driven PROVEN Skincare Announces Launch of $60 Million Regulation A+ Offering | PROVEN Skincare (“PROVEN” or the “Company”), an AI-powered, technology first consumer company that formulates and markets personalized skincare products, announced today the launch of its Regulation A+ equity funding campaign following the ... |
| 05.10.2021 | Stealth BioTherapeutics : Completes a $25 Million Debt Financing with Horizon Technology Finance | BOSTON - Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced complet... |
| 06.10.2020 | A2 Biotherapeutics : Closes $71.5M Series B to Begin Clinical Development of Its Potentially Transformative Selective Tumor Cell Therapeutics | A2 Biotherapeutics (www.a2bio.com), a biotechnology company developing innovative cell therapies for solid tumor cancer patients, today announced the closing of its $71.5M Series B financing. Proceeds will fund the advancement of its Tmod (... |
| 23.09.2020 | SBC occupier Immune Regulation Limited raises £40.6 million Series B equity financing | SBC occupier Immune Regulation Limited raises £40.6 million Series B equity financing 23-09-2020 Series B round led by Morningside Ventures provides foundation to accelerate the drug development of first-in-class immune-resetting therapies.... |
| 23.09.2020 | Immune Regulation lands $53.4M Series B | Morningside Ventures has led a $53.4 million investment in Immune Regulation, with support from investors including 24Haymarket. As part of the round, Metellus AG led $7.8 million in advance subscription funds for the company. Based near Ca... |
| 21.09.2020 | Immune Regulation raises $53m Series B round led by Morningside Ventures | - |
| 21.09.2020 | Morningside ventures invests $54m in Immune Regulation, a GWC portfolio company | Series B round led by Morningside Ventures provides foundation to accelerate the drug development of first-in-class immune-resetting therapies. (London UK and Boston USA, 21 September 2020) Immune Regulation Limited (“Immune Regulation”), a... |
| 21.09.2020 | Immune Regulation Raises £40.6M in Series B Equity Financing | Immune Regulation Limited, a US and UK based clinical stage biotechnology company, closed a $40.6m Series B funding round. The round was led by Morningside Ventures, alongside existing shareholders including London based 24Haymarket. The in... |
| 21.06.2020 | GWC members invest £700k in Immune Regulation | Immune Regulation is a clinical stage biotech company, pioneering new technologies for resetting the immune system, developing novel, first-in-class therapies for inflammatory and immunological diseases. |
| 22.11.2018 | 24Haymarket co-leads £4m investment in Immune Regulation | - |